Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
K-232
- Development stage
- Unknown
- Lead developer
- Kowa
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
K-232 is a Rho-kinase (ROCK) inhibitor developed by Kowa Company, Ltd. for the treatment of primary open-angle glaucoma, exfoliative glaucoma, pigmentary glaucoma, and ocular hypertension. It is a new formulation of ripasudil hydrochloride hydrate (originally developed as K-115) optimized for once-daily ophthalmic administration. By inhibiting ROCK1 and ROCK2, K-232 promotes the outflow of aqueous humor through the trabecular meshwork, thereby reducing intraocular pressure. As of 2024, it is in Phase 3 clinical development in Japan, where it is being evaluated for long-term safety and efficacy both as a monotherapy and in combination with other intraocular pressure-lowering agents.
- Other names
- ripasudil hydrochloride hydrate
02
Targets
ADRA2A (α2A)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Beyond the preview
Go deeper on K-232.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on K-232.